Share Name Share Symbol Market Type Share ISIN Share Description
Ergomed LSE:ERGO London Ordinary Share GB00BN7ZCY67 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50p -1.33% 185.00p 185.00p 190.00p 187.50p 185.00p 187.50p 5,298 16:35:17
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 39.2 0.3 1.3 142.3 78.96

Ergomed Share Discussion Threads

Showing 201 to 223 of 225 messages
Chat Pages: 9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
12/12/2017
09:52
https://www.investegate.co.uk/ergomed-plc--ergo-/rns/co-dev-partnership-with-allergy-therapeutics/201712120700040254Z/
amchw
01/11/2017
18:08
Thanks - will be interesting not to follow the development of PeproStat.
bermudashorts
01/11/2017
10:11
EQUITY DEVELOPMENT EQUITY DEVELOPMENT CHAMPIONING GROWTH COMPANIES Ergomed : Positive PeproStat Data Symbol ERGO Listing AIM Share Price 210p Market Cap £89.6m Sector Healthcare Published 01/11/17 Analyst Elizabeth Klein Recently announced results from the phase II clinical trial of PeproStat were positive. As a result, the probability of PeproStat reaching the market increased from around a third to around two-thirds. This adds £12.7m to the valuation of this programme. As expected the shares saw strong performance on the back of the positive data. There remains significant upside to the bottom end of our 276p-401p valuation. Ergomed acquired Haemostatix in May 2016 for £28m (an initial £8.0m upfront, with the remainder in success-based milestone payments). Haemostatix had developed a new approach to controlling bleeding using a peptide that binds to fibrinogen, targeting a surgical market valued at c. US$2.5bn, growing at c. 6.2% pa. The phase II trial consisted of 169 patients treated (162 evaluable) at 16 sites in five European countries. PeproStat was shown to be clinically and significantly superior to standard of care across three surgery types. The mean time to Haemostasis was reduced by 1.55 minutes for PeproStat vs. standard of care, and favourable by investigator opinion (80.9% surgeons rated PeproStat (blinded) as good to excellent in controlling bleeding vs 59.6% for standard of care). The first commercial deal for a Haemsotatix product was signed late September with a South Korean company, Boryung Pharmaceutical Co. Ergomed will receive an upfront payment and a series of milestone payments as well as a double-digit share of all future product sales in this territory. Further PeproStat deals, along with the start of the next trial in H2 2018 and initial ReadyFlow data, should feature in the news flow over the next 12-18 months, along with further acquisitions to boost the profitability of the Services business. The bottom of the 276p - 401p per share valuation is based on the more conservative “Services-only” sales forecast, discounting completely the potential upside from Development projects. The top of the range adds in these projects with the Haeomstatix programme now making up 60% of the Development valuation.
douglas fir
24/10/2017
19:17
hxxps://youtu.be/FFCT_F8zDpQ
mfhmfh
23/10/2017
20:05
Interview with Andrew Mackie here:- hxxps://www.goinpharma.com/en/new-antibiotic-therapies-what-future/ Link to more detailed presentation of Peprostat clinical trial results here:- hxxp://www.ergomedplc.com/investor-relations/reports-presentations
bermudashorts
23/10/2017
17:17
Good to see Singers sum of the parts valuation raised to 367p -a long way to go yet. When further licensing deals are announced the shares are likely to strengthen further as the scale of the opportunity becomes more apparent
buffetteer
23/10/2017
10:09
HTTP://labiotech.eu/ergomed-peprostat-surgery/
mirabeau
23/10/2017
10:07
Nice write up here from Labiotech hxxps://labiotech.eu/ergomed-peprostat-surgery/
bermudashorts
23/10/2017
08:40
Sounds like they will licence out the product prior to Phase 3 so will lose control of the timing.
jamtomorrow2
23/10/2017
08:35
Piedro Yes, maybe, but I'm now wondering if there may some sort of sliding scale as suggested by BB. But if not, then it may be in their interest to commence the study prior to conducting a placing of that size.
timbo003
23/10/2017
08:32
BB, well spotted, I don't know the answer to that one, but I now intend to make enquiries if I get an opportune moment.
timbo003
23/10/2017
08:19
Timbo, Possibly, although it states 'up to £4m. Why use the words 'up to' - suggests there are some variables in the agreement. Any ideas what they could be?
bermudashorts
23/10/2017
08:19
timbo003, If so, they will be looking for £14m {placing?}, reckoning that the extra cash will bring MC close to the £100m
piedro
23/10/2017
08:14
mfhmfh, "anyone know when Phase III will be starting/finishing?" - read the presentation
piedro
23/10/2017
08:11
Re: post #208 The current market cap is £84, so if the phase III study were to start with the share price where is is now, presumably the milestone (equivalent to around 16p/share) would not be payable, if the share price were to rise to around 245p/share, then it would be payable. That suggests to me that for now, the maximum upside for the share is around 245p in the absence of any further substantial news.
timbo003
23/10/2017
07:43
I suspect there may be another £4m to add to the costs, see below from the ED initiation report:
timbo003
23/10/2017
07:41
Positive Phase II results should hopefully bring more investors on board. anyone know when Phase III will be starting/finishing?
mfhmfh
23/10/2017
07:28
NEXT STEPS Phase III • 600 patients, £10m • Complete recruitment 2019 - How's the bank account?
piedro
23/10/2017
07:24
Yes - good news. Liked this part of the RNS:- "Currently, we have a number of active licensing and partnering discussions to fund further development.""
bermudashorts
23/10/2017
07:17
Have a nice position here and think we will gain steadily. What's the price target 500p?
money maker1
23/10/2017
07:13
That was a nice decisive result ED previously valued Haemostatix at £12.1M with a 36% PTS and they stated that if Haemostatix succeeds in this latest phase II it should increase to a 63% PTS i.e. to around £20m which is an increase of approximately £8m in valuation (or around 20p/share).
timbo003
20/10/2017
14:30
Ergomed plc Well-positioned ahead of PeproStat data hTTps://www.equitydevelopment.co.uk/edreader/?d=%3D%3DQM1MjM
piedro
20/10/2017
10:26
Ergomed offers clinical trial and pharmacovigilance services to pharmaceutical companies, while also co-developing a product portfolio of therapies. Ahead of the PeproStat data expected toward the end of this month, Ergomed recently improved its competitive position for its Services businesses with its acquisition of PSR in the Orphan Drug/Rare Disease. At the same time, it signed its first deal for PeproStat (and ReadyFlow), suggesting attractive commercialisation opportunities awaiting the data at the end of the month. Excitingly, the first commercial deal for a Haemsotatix product, PeproStat for the treatment of surgical bleeding was signed late September, having completed the recruitment of its 169 patient Phase IIb trial in July, six months ahead of schedule. A positive result from this clinical trial could increase the probability of success from 36% to 63% (as estimated by BIO for this therapeutic area) in the valuation analysis, nearly doubling the valuation for this programme. hxxps://www.equitydevelopment.co.uk/ The expected news flow for the rest of 2017 and into 2018 is focused on the outcome of the PeproStat Haemostatix trial data, further acquisitions to boost the profitability of the Clinical Research Services businesses may occur and more contract wins are likely. The bottom of the range of our increased 281p-397p per share valuation is based on the more conservative “Services-only” sales forecast, discounting completely the potential upside from the attractive Products and Co-Development projects. The top of the range adds in these Product and Co-development projects. With significant upside to the bottom end of our valuation, the shares could see strong performance on the back of positive clinical data.
douglas fir
Chat Pages: 9  8  7  6  5  4  3  2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20171213 17:08:01